MX2023005865A - Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. - Google Patents
Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.Info
- Publication number
- MX2023005865A MX2023005865A MX2023005865A MX2023005865A MX2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydrofuropyridine
- derivatives
- compounds
- rho
- kinase inhibitors
- Prior art date
Links
- PJVQPPHJEYPUDB-UHFFFAOYSA-N 2,3-dihydrofuro[3,2-b]pyridine Chemical class C1=CC=C2OCCC2=N1 PJVQPPHJEYPUDB-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000000568 rho-Associated Kinases Human genes 0.000 abstract 1
- 108010041788 rho-Associated Kinases Proteins 0.000 abstract 1
- 239000011435 rock Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a compuestos de la fórmula (I) que inhiben la Rho cinasa que son derivados de la dihidrofuropiridina, métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Particularmente, los compuestos de la invención pueden ser útiles en el tratamiento de muchos trastornos asociados con mecanismos de enzimas ROCK, tal como enfermedades pulmonares que incluyen asma, enfermedad pulmonar obstructiva crónica (COPD), fibrosis pulmonar idiopática (IPF) e hipertensión arterial pulmonar (PAH).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20214148 | 2020-12-15 | ||
| PCT/EP2021/085378 WO2022128851A1 (en) | 2020-12-15 | 2021-12-13 | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005865A true MX2023005865A (es) | 2023-06-05 |
Family
ID=73854548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005865A MX2023005865A (es) | 2020-12-15 | 2021-12-13 | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240092792A1 (es) |
| EP (1) | EP4263546A1 (es) |
| JP (1) | JP2023552901A (es) |
| KR (1) | KR20230121811A (es) |
| CN (1) | CN116568303A (es) |
| AU (1) | AU2021403631A1 (es) |
| CA (1) | CA3202126A1 (es) |
| MX (1) | MX2023005865A (es) |
| WO (1) | WO2022128851A1 (es) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4681451B2 (ja) | 2002-10-28 | 2011-05-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類 |
| EP1756092A4 (en) | 2004-06-17 | 2009-12-02 | Smithkline Beecham Corp | NEW INHIBITORS OF RHO-KINASEN |
| WO2009079008A1 (en) | 2007-12-19 | 2009-06-25 | Yangbo Feng | Benzopyrans and analogs as rho kinase inhibitors |
| JP2012502882A (ja) | 2008-09-18 | 2012-02-02 | アステラス製薬株式会社 | 複素環カルボキサミド化合物 |
| CA2804744C (en) | 2010-07-14 | 2019-05-28 | Novartis Ag | Ip receptor agonist 1,8-naphthyridinyl and 7,8-dihydropyrido[3,2-b]pyrazinyl heterocyclic compounds |
| SG11201505867PA (en) | 2013-01-29 | 2015-08-28 | Amakem Nv | Pyridine derivatives as soft rock inhibitors |
| AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
| PL3573987T3 (pl) | 2017-01-30 | 2021-08-30 | Chiesi Farmaceutici S.P.A. | Pochodne amidu tyrozynowego jako inhibitory kinazy Rho |
| MA50074A (fr) | 2017-09-07 | 2021-04-28 | Chiesi Farm Spa | Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase |
| US11578068B2 (en) | 2017-12-18 | 2023-02-14 | Chiesi Farmaceutici S.P.A. | Oxadiazole derivatives as Rho-Kinase Inhibitors |
| WO2019121223A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Meta tyrosine derivatives as rho-kinase inhibitors |
| WO2019121406A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Azaindole derivatives as rho-kinase inhibitors |
| AR114926A1 (es) | 2018-06-13 | 2020-10-28 | Chiesi Farm Spa | Derivados de azaindol como inhibidores de rho-quinasa |
| TW202019923A (zh) | 2018-07-16 | 2020-06-01 | 義大利商吉斯藥品公司 | 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物 |
-
2021
- 2021-12-13 KR KR1020237023627A patent/KR20230121811A/ko unknown
- 2021-12-13 CN CN202180084238.5A patent/CN116568303A/zh active Pending
- 2021-12-13 CA CA3202126A patent/CA3202126A1/en active Pending
- 2021-12-13 EP EP21824399.6A patent/EP4263546A1/en active Pending
- 2021-12-13 AU AU2021403631A patent/AU2021403631A1/en active Pending
- 2021-12-13 US US18/267,222 patent/US20240092792A1/en active Pending
- 2021-12-13 WO PCT/EP2021/085378 patent/WO2022128851A1/en active Application Filing
- 2021-12-13 JP JP2023536037A patent/JP2023552901A/ja active Pending
- 2021-12-13 MX MX2023005865A patent/MX2023005865A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240092792A1 (en) | 2024-03-21 |
| WO2022128851A1 (en) | 2022-06-23 |
| KR20230121811A (ko) | 2023-08-21 |
| CN116568303A (zh) | 2023-08-08 |
| JP2023552901A (ja) | 2023-12-19 |
| CA3202126A1 (en) | 2022-06-23 |
| AU2021403631A1 (en) | 2023-07-27 |
| EP4263546A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402319B1 (ar) | Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| MX2021014113A (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
| MX2021000270A (es) | Derivados de la tirosina amida como inhibidores de la rho- cinasa. | |
| NO20070076L (no) | Nye indazolkarboksamider og deres anvendelse | |
| MX2007013216A (es) | Derivados de amida substituida como inhibidores de la proteina de cinasa. | |
| MX2009009443A (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds. | |
| MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| SG155932A1 (en) | Chemical compounds | |
| MX2009010270A (es) | Indol carboxamidas como inhibidores de quinasas ikappa2. | |
| MX2020012202A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas. | |
| MX2021012749A (es) | Inhibidor selectivo de la jak1 cinasa. | |
| EA200800183A1 (ru) | Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения | |
| TN2009000452A1 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MX2023005866A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
| MX2023005867A (es) | Derivados de dihidrofuropiridina como inhibidores de la cinasa rho. | |
| MX2023005865A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
| MX2021014116A (es) | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
| NO20081483L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma |